Bionomics price target raised to $10 from $7 at Maxim

Maxim analyst Jason McCarthy raised the firm’s price target on Bionomics to $10 from $7 and keeps a Buy rating on the shares after the company reported that its Phase 2b ATTUNE study in PTSD met its primary endpoint with a significant reduction in PTSD symptom severity versus placebo. This initial data in PTSD “makes a compelling case for BNC210,” says the firm, which lowers its revenue risk adjustment to 60%, from 80%, which increases its price target on the shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on BNOX:

Disclaimer & DisclosureReport an Issue